[{"orgOrder":0,"company":"Beijing Sungen Biomedical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"SGC001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Beijing Sungen Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Sungen Biomedical Technology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Sungen Biomedical Technology \/ Inapplicable"},{"orgOrder":0,"company":"Argo Biopharma","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Licensing Agreement","leadProduct":"BW-02","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Argo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Argo Biopharma \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Argo Biopharma \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Sanegene Bio","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"SGB-3908","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Sanegene Bio","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Sanegene Bio"},{"orgOrder":0,"company":"Drug Farm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"8-Bromo-pet-cyclic gmps","moa":"ALPK1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Drug Farm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Drug Farm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Drug Farm \/ Inapplicable"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Carlyle","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"JK07","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Carlyle","highestDevelopmentStatusID":"6","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Carlyle"},{"orgOrder":0,"company":"YolTech Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"YOLT-101","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"YolTech Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YolTech Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"YolTech Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"YolTech Therapeutics","sponsor":"SHENZHEN SALUBRIS PHARMACEUTICALS","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"YOLT-101","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"YolTech Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YolTech Therapeutics \/ SHENZHEN SALUBRIS PHARMACEUTICALS","highestDevelopmentStatusID":"6","companyTruncated":"YolTech Therapeutics \/ SHENZHEN SALUBRIS PHARMACEUTICALS"},{"orgOrder":0,"company":"Rona Therapeutics","sponsor":"LongRiver Investments","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Series A Financing","leadProduct":"RN0191","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Rona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rona Therapeutics \/ LongRiver Investments","highestDevelopmentStatusID":"6","companyTruncated":"Rona Therapeutics \/ LongRiver Investments"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ASC41","moa":"TH-beta-receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Rona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"RN0361","moa":"APOC-3 mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Rona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GFH312","moa":"RIPK1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GenFleet Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GenFleet Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"YolTech Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"YOLT-101","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"YolTech Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"YolTech Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"YolTech Therapeutics \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : YOLT-101 is a next-generation in vivo base-editing therapeutic, being evaluating in the early-stage clinical trial studies for the treatment of Familial Hypercholesterolemia.

                          Product Name : YOLT-101

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          April 28, 2025

                          Lead Product(s) : YOLT-101

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : SGC001 is a monoclonal antibody, which is currently being evaluated for the treatment of patients suffering from acute myocardial infarction.

                          Product Name : SGC001

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          March 24, 2025

                          Lead Product(s) : SGC001

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : RN0361 is a potential best-in-class APOC3 target siRNA, which is currently being evaluated for the treatment of severe hypertriglyceridemia.

                          Product Name : RN0361

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          March 17, 2025

                          Lead Product(s) : RN0361

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : YolTech will continue to advance the preclinical development of YOLT-101, while Salubris will be responsible for preparing and conducting clinical trials within the licensed territory.

                          Product Name : YOLT-101

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          August 27, 2024

                          Lead Product(s) : YOLT-101

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : SHENZHEN SALUBRIS PHARMACEUTICALS

                          Deal Size : $145.3 million

                          Deal Type : Licensing Agreement

                          blank

                          05

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The financing aims to fund the clinical development of the company's first program RN0191, a best-in-class PCSK9 siRNA program, which is being evaluated for treating Hypercholesteremia.

                          Product Name : RN0191

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          July 19, 2024

                          Lead Product(s) : RN0191

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : LongRiver Investments

                          Deal Size : $35.0 million

                          Deal Type : Series A Financing

                          blank

                          06

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Argo has granted Novartis global licenses to develop and commercialize a Phase 1 program, allowing Novartis to select targets and drive discovery and optimization of lead candidates.

                          Product Name : BW-02

                          Product Type : Oligonucleotide

                          Upfront Cash : $185.0 million

                          July 01, 2024

                          Lead Product(s) : BW-02

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Novartis Pharmaceuticals Corporation

                          Deal Size : $4,165.0 million

                          Deal Type : Licensing Agreement

                          blank

                          07

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : YOLT-101, the company's in vivo genome editing candidate being developed as a single dose, potentially curative therapy for the treatment of high-risk heterozygous familial hypercholesterolemia.

                          Product Name : YOLT-101

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          February 04, 2024

                          Lead Product(s) : YOLT-101

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : IBI3016 (SGB-3908) is an siRNA drug candidate targeting and reduces angiotensinogen (AGT) level in serum, in patients with essential hypertension.

                          Product Name : SGB-3908

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          January 08, 2024

                          Lead Product(s) : SGB-3908

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Sanegene Bio

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : DF-003, discovered through Drug Farms’ IDInVivo and MedChem5 platform technologies, is an investigational small molecule drug that inhibits alpha-kinase 1 (ALPK1), a key target regulating inflammation pathways that underly disease pathology in cardio-r...

                          Product Name : DF-003

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 19, 2023

                          Lead Product(s) : 8-Bromo-pet-cyclic gmps

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Preclinical data demonstrated GFH312 is able to inhibit RIPK1 kinase activity in human cells, down-regulate RIPK1 phosphorylation in animal models and curb the inflammatory response of animals' nervous system.

                          Product Name : GFH312

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 18, 2022

                          Lead Product(s) : GFH312

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank